- Home
- TXO vs GERN Comparison
TXO vs GERN Comparison
Compare TXO & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TXO
- GERN
- Stock Information
- Founded
- TXO 2012
- GERN 1990
- Country
- TXO United States
- GERN United States
- Employees
- TXO N/A
- GERN N/A
- Industry
- TXO Oil & Gas Production
- GERN Biotechnology: Pharmaceutical Preparations
- Sector
- TXO Energy
- GERN Health Care
- Exchange
- TXO Nasdaq
- GERN Nasdaq
- Market Cap
- TXO 806.1M
- GERN 853.5M
- IPO Year
- TXO 2023
- GERN 1996
- Fundamental
- Price
- TXO $14.95
- GERN $1.57
- Analyst Decision
- TXO
- GERN Buy
- Analyst Count
- TXO 0
- GERN 9
- Target Price
- TXO N/A
- GERN $5.13
- AVG Volume (30 Days)
- TXO 426.7K
- GERN 13.0M
- Earning Date
- TXO 05-01-2025
- GERN 05-07-2025
- Dividend Yield
- TXO 15.84%
- GERN N/A
- EPS Growth
- TXO N/A
- GERN N/A
- EPS
- TXO 0.40
- GERN N/A
- Revenue
- TXO $299,696,000.00
- GERN $116,293,000.00
- Revenue This Year
- TXO $19.72
- GERN $160.12
- Revenue Next Year
- TXO N/A
- GERN $55.01
- P/E Ratio
- TXO $37.08
- GERN N/A
- Revenue Growth
- TXO 3.43
- GERN 22264.04
- 52 Week Low
- TXO $14.85
- GERN $1.17
- 52 Week High
- TXO $22.39
- GERN $5.34
- Technical
- Relative Strength Index (RSI)
- TXO 29.28
- GERN 51.71
- Support Level
- TXO $15.01
- GERN $1.30
- Resistance Level
- TXO $15.74
- GERN $1.54
- Average True Range (ATR)
- TXO 0.49
- GERN 0.11
- MACD
- TXO -0.04
- GERN 0.03
- Stochastic Oscillator
- TXO 3.28
- GERN 66.67
About TXO TXO Partners L.P.
TXO Partners LP is focused on the acquisition, development, optimization, and exploitation of oil, natural gas, and natural gas liquid reserves in North America.
About GERN Geron Corporation
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.